Navdeep Pal

1.1k total citations · 1 hit paper
26 papers, 689 citations indexed

About

Navdeep Pal is a scholar working on Obstetrics and Gynecology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Navdeep Pal has authored 26 papers receiving a total of 689 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Obstetrics and Gynecology, 9 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Navdeep Pal's work include Endometrial and Cervical Cancer Treatments (10 papers), Ovarian cancer diagnosis and treatment (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Navdeep Pal is often cited by papers focused on Endometrial and Cervical Cancer Treatments (10 papers), Ovarian cancer diagnosis and treatment (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Navdeep Pal collaborates with scholars based in United States, Switzerland and United Kingdom. Navdeep Pal's co-authors include Shannon N. Westin, Pamela T. Soliman, Diana L. Urbauer, Diane C. Bodurka, Lois M. Ramondetta, Shemra Rizzo, Ryan Copping, James Zou, Ruishan Liu and Karen H. Lu and has published in prestigious journals such as Nature, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Navdeep Pal

25 papers receiving 677 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluating eligibility criteria of oncology trials using real-world data and AI

2021 184 citations Ruishan Liu, Shemra Rizzo et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Navdeep Pal United States	11	270	189	182	127	91	26	689
Giovanni M. Bariani Brazil	12	177 0.7×	443 2.3×	119 0.7×	201 1.6×	112 1.2×	32	839
Jason C. Barnett United States	18	295 1.1×	211 1.1×	350 1.9×	79 0.6×	136 1.5×	33	911
Peey‐Sei Kok Australia	14	120 0.4×	252 1.3×	99 0.5×	236 1.9×	35 0.4×	38	555
Lawrence R. Ragard United States	13	242 0.9×	253 1.3×	492 2.7×	360 2.8×	168 1.8×	28	1.1k
V. Van Belle Belgium	11	283 1.0×	71 0.4×	366 2.0×	34 0.3×	49 0.5×	16	628
Sarah Kenny United Kingdom	12	116 0.4×	431 2.3×	83 0.5×	265 2.1×	65 0.7×	22	751
G. Bastert Germany	17	96 0.4×	494 2.6×	69 0.4×	80 0.6×	161 1.8×	94	1.2k
Larry Léon United States	12	108 0.4×	211 1.1×	264 1.5×	770 6.1×	45 0.5×	23	1.3k
Larry G. Maxwell United States	8	188 0.7×	199 1.1×	137 0.8×	76 0.6×	111 1.2×	12	528
Tsuyoshi Takiuchi Japan	17	455 1.7×	148 0.8×	247 1.4×	65 0.5×	173 1.9×	60	907

Countries citing papers authored by Navdeep Pal

Since Specialization

Citations

This map shows the geographic impact of Navdeep Pal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Navdeep Pal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Navdeep Pal more than expected).

Fields of papers citing papers by Navdeep Pal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Navdeep Pal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Navdeep Pal. The network helps show where Navdeep Pal may publish in the future.

Co-authorship network of co-authors of Navdeep Pal

This figure shows the co-authorship network connecting the top 25 collaborators of Navdeep Pal. A scholar is included among the top collaborators of Navdeep Pal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Navdeep Pal. Navdeep Pal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Provencio, Mariano, Haroon Hasan, Begoña Campos, et al.. (2024). Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer. Clinical & Translational Oncology. 26(6). 1384–1394. 3 indexed citations

Budde, Lihua E., Adam J. Olszewski, Connie Lee Batlevi, et al.. (2024). Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data. Blood. 144(Supplement 1). 2373–2373.

Polito, Letizia, Navdeep Pal, Ahmed Sawas, et al.. (2024). Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting. Frontiers in Pharmacology. 15. 1223858–1223858. 4 indexed citations

Liu, Ruishan, Lisa Wang, Shemra Rizzo, et al.. (2024). Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients. Cell Reports Medicine. 5(3). 101444–101444. 8 indexed citations

Zhang, Qing, W. Marston Linehan, Navdeep Pal, et al.. (2023). Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases. JTO Clinical and Research Reports. 4(4). 100483–100483. 7 indexed citations

Julián, Cristina, Navdeep Pal, Anda Gershon, et al.. (2023). Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting. BMC Cancer. 23(1). 352–352. 10 indexed citations

Ton, Thanh G.N., Navdeep Pal, Huong Trinh, et al.. (2022). Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data. Clinical Cancer Research. 28(13). 2844–2853. 13 indexed citations

Pérol, M., Enriqueta Felip, Urania Dafni, et al.. (2022). Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Annals of Oncology. 33(5). 511–521. 52 indexed citations

Wu, Kevin, Eric Wu, Marek Dąbrowski, et al.. (2022). Machine Learning Prediction of Clinical Trial Operational Efficiency. The AAPS Journal. 24(3). 57–57. 14 indexed citations

10.

Liu, Ruishan, Shemra Rizzo, Sarah Waliany, et al.. (2022). Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data. Nature Medicine. 28(8). 1656–1661. 21 indexed citations

11.

Liu, Ruishan, Shemra Rizzo, Samuel Whipple, et al.. (2021). Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature. 592(7855). 629–633. 184 indexed citations breakdown →

12.

Julián, Cristina, Navdeep Pal, Anda Gershon, et al.. (2021). Abstract 660: Real-world prevalence of metastasis and overall survival (OS) in patients with advanced non-small cell lung cancer (aNSCLC) with KRAS G12C and with or without STK11 or KEAP1 mutations. Cancer Research. 81(13_Supplement). 660–660. 1 indexed citations

13.

Peters, Solange, Urania Dafni, M. Pérol, et al.. (2021). VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data. Annals of Oncology. 32(5). 687–688. 11 indexed citations

14.

Westin, Shannon N., Bryan Fellman, Charlotte C. Sun, et al.. (2020). Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. American Journal of Obstetrics and Gynecology. 224(2). 191.e1–191.e15. 77 indexed citations

15.

Holman, Laura L., Navdeep Pal, David A. Iglesias, et al.. (2017). Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecologic Oncology. 146(1). 27–33. 19 indexed citations

16.

Pal, Navdeep, Russell R. Broaddus, Diana L. Urbauer, et al.. (2017). Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstetrics and Gynecology. 131(1). 109–116. 130 indexed citations

17.

Soliman, Pamela T., Alpa M. Nick, Charlotte C. Sun, et al.. (2016). Obesity significantly reduces the sentinel lymph node detection rate in women with endometrial cancer. Gynecologic Oncology. 141. 31–31. 1 indexed citations

18.

Westin, Shannon N., Zhenlin Ju, Russell R. Broaddus, et al.. (2015). PTEN loss is a context‐dependent outcome determinant in obese and non‐obese endometrioid endometrial cancer patients. Molecular Oncology. 9(8). 1694–1703. 42 indexed citations

19.

Holman, Laura L., David A. Iglesias, Pamela T. Soliman, et al.. (2013). Long-term survival in advanced-stage uterine papillary serous carcinoma.. Journal of Clinical Oncology. 31(15_suppl). 5596–5596. 1 indexed citations

20.

Westin, Shannon N., Navdeep Pal, Diana L. Urbauer, et al.. (2013). Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2611–2611. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact